The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) Stock Competitors & Peer Comparison
See (COO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| COO | $82.47 | -1.45% | 16.7B | 44.96 | $1.87 | N/A |
| ISRG | $489.27 | -2.05% | 179B | 63.88 | $7.89 | N/A |
| BDX | $183.05 | +0.32% | 67.2B | 30.29 | $6.12 | +1.78% |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +1.78% |
| ALC | $82.72 | -0.61% | 40.9B | 39.35 | $2.10 | +0.41% |
| MDLN | $49.59 | +4.18% | 40.4B | 72.17 | $0.69 | N/A |
| RMD | $261.35 | +1.97% | 37.8B | 25.66 | $10.10 | +0.90% |
| WST | $243.60 | -0.10% | 17.4B | 35.48 | $6.80 | +0.36% |
| HOLX | $75.43 | +0.38% | 16.8B | 31.30 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +1.78% |
Stock Comparison
COO vs ISRG Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, ISRG has a market cap of 179B. Regarding current trading prices, COO is priced at $82.47, while ISRG trades at $489.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas ISRG's P/E ratio is 63.88. In terms of profitability, COO's ROE is +0.05%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, COO is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check ISRG's competition here
COO vs BDX Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, BDX has a market cap of 67.2B. Regarding current trading prices, COO is priced at $82.47, while BDX trades at $183.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas BDX's P/E ratio is 30.29. In terms of profitability, COO's ROE is +0.05%, compared to BDX's ROE of +0.07%. Regarding short-term risk, COO is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check BDX's competition here
COO vs BDXA Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, COO is priced at $82.47, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas BDXA's P/E ratio is 21.44. In terms of profitability, COO's ROE is +0.05%, compared to BDXA's ROE of +0.07%. Regarding short-term risk, COO is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check BDXA's competition here
COO vs ALC Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, ALC has a market cap of 40.9B. Regarding current trading prices, COO is priced at $82.47, while ALC trades at $82.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas ALC's P/E ratio is 39.35. In terms of profitability, COO's ROE is +0.05%, compared to ALC's ROE of +0.05%. Regarding short-term risk, COO is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check ALC's competition here
COO vs MDLN Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, MDLN has a market cap of 40.4B. Regarding current trading prices, COO is priced at $82.47, while MDLN trades at $49.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas MDLN's P/E ratio is 72.17. In terms of profitability, COO's ROE is +0.05%, compared to MDLN's ROE of +0.08%. Regarding short-term risk, COO is more volatile compared to MDLN. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check MDLN's competition here
COO vs RMD Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, RMD has a market cap of 37.8B. Regarding current trading prices, COO is priced at $82.47, while RMD trades at $261.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas RMD's P/E ratio is 25.66. In terms of profitability, COO's ROE is +0.05%, compared to RMD's ROE of +0.25%. Regarding short-term risk, COO is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check RMD's competition here
COO vs WST Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, WST has a market cap of 17.4B. Regarding current trading prices, COO is priced at $82.47, while WST trades at $243.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas WST's P/E ratio is 35.48. In terms of profitability, COO's ROE is +0.05%, compared to WST's ROE of +0.17%. Regarding short-term risk, COO is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check WST's competition here
COO vs HOLX Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, HOLX has a market cap of 16.8B. Regarding current trading prices, COO is priced at $82.47, while HOLX trades at $75.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas HOLX's P/E ratio is 31.30. In terms of profitability, COO's ROE is +0.05%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, COO is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check HOLX's competition here
COO vs BDXB Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, COO is priced at $82.47, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas BDXB's P/E ratio is 7.60. In terms of profitability, COO's ROE is +0.05%, compared to BDXB's ROE of +0.07%. Regarding short-term risk, COO is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check BDXB's competition here
COO vs BAX Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, BAX has a market cap of 11.1B. Regarding current trading prices, COO is priced at $82.47, while BAX trades at $21.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas BAX's P/E ratio is -12.33. In terms of profitability, COO's ROE is +0.05%, compared to BAX's ROE of -0.12%. Regarding short-term risk, COO is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check BAX's competition here
COO vs ATR Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, ATR has a market cap of 9.5B. Regarding current trading prices, COO is priced at $82.47, while ATR trades at $145.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas ATR's P/E ratio is 24.63. In terms of profitability, COO's ROE is +0.05%, compared to ATR's ROE of +0.15%. Regarding short-term risk, COO is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check ATR's competition here
COO vs MASI Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, COO is priced at $82.47, while MASI trades at $175.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas MASI's P/E ratio is -38.48. In terms of profitability, COO's ROE is +0.05%, compared to MASI's ROE of -0.59%. Regarding short-term risk, COO is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check MASI's competition here
COO vs RGEN Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, RGEN has a market cap of 7.6B. Regarding current trading prices, COO is priced at $82.47, while RGEN trades at $133.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas RGEN's P/E ratio is 13568.00. In terms of profitability, COO's ROE is +0.05%, compared to RGEN's ROE of +0.00%. Regarding short-term risk, COO is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check RGEN's competition here
COO vs BLCO Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, BLCO has a market cap of 6.4B. Regarding current trading prices, COO is priced at $82.47, while BLCO trades at $17.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas BLCO's P/E ratio is -20.87. In terms of profitability, COO's ROE is +0.05%, compared to BLCO's ROE of -0.06%. Regarding short-term risk, COO is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check BLCO's competition here
COO vs AVTR Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, AVTR has a market cap of 6.1B. Regarding current trading prices, COO is priced at $82.47, while AVTR trades at $8.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas AVTR's P/E ratio is -11.56. In terms of profitability, COO's ROE is +0.05%, compared to AVTR's ROE of -0.09%. Regarding short-term risk, COO is more volatile compared to AVTR. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check AVTR's competition here
COO vs TFX Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, TFX has a market cap of 5.1B. Regarding current trading prices, COO is priced at $82.47, while TFX trades at $111.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas TFX's P/E ratio is -16.11. In terms of profitability, COO's ROE is +0.05%, compared to TFX's ROE of -0.08%. Regarding short-term risk, COO is less volatile compared to TFX. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check TFX's competition here
COO vs MMSI Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, MMSI has a market cap of 4.9B. Regarding current trading prices, COO is priced at $82.47, while MMSI trades at $81.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas MMSI's P/E ratio is 42.16. In terms of profitability, COO's ROE is +0.05%, compared to MMSI's ROE of +0.08%. Regarding short-term risk, COO is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check MMSI's competition here
COO vs STVN Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, STVN has a market cap of 4.4B. Regarding current trading prices, COO is priced at $82.47, while STVN trades at $16.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas STVN's P/E ratio is 26.72. In terms of profitability, COO's ROE is +0.05%, compared to STVN's ROE of +0.10%. Regarding short-term risk, COO is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check STVN's competition here
COO vs ICUI Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, COO is priced at $82.47, while ICUI trades at $151.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas ICUI's P/E ratio is -506.55. In terms of profitability, COO's ROE is +0.05%, compared to ICUI's ROE of +0.00%. Regarding short-term risk, COO is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check ICUI's competition here
COO vs WRBY Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, WRBY has a market cap of 2.9B. Regarding current trading prices, COO is priced at $82.47, while WRBY trades at $22.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas WRBY's P/E ratio is -296.37. In terms of profitability, COO's ROE is +0.05%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, COO is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check WRBY's competition here
COO vs HAE Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, HAE has a market cap of 2.9B. Regarding current trading prices, COO is priced at $82.47, while HAE trades at $60.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas HAE's P/E ratio is 16.86. In terms of profitability, COO's ROE is +0.05%, compared to HAE's ROE of +0.20%. Regarding short-term risk, COO is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check HAE's competition here
COO vs XRAY Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, XRAY has a market cap of 2.5B. Regarding current trading prices, COO is priced at $82.47, while XRAY trades at $12.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas XRAY's P/E ratio is -2.85. In terms of profitability, COO's ROE is +0.05%, compared to XRAY's ROE of -0.48%. Regarding short-term risk, COO is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check XRAY's competition here
COO vs LMAT Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, LMAT has a market cap of 2.1B. Regarding current trading prices, COO is priced at $82.47, while LMAT trades at $92.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas LMAT's P/E ratio is 40.06. In terms of profitability, COO's ROE is +0.05%, compared to LMAT's ROE of +0.15%. Regarding short-term risk, COO is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check LMAT's competition here
COO vs ATRC Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, ATRC has a market cap of 1.6B. Regarding current trading prices, COO is priced at $82.47, while ATRC trades at $31.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas ATRC's P/E ratio is -53.41. In terms of profitability, COO's ROE is +0.05%, compared to ATRC's ROE of -0.02%. Regarding short-term risk, COO is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check ATRC's competition here
COO vs KMTS Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, KMTS has a market cap of 1.5B. Regarding current trading prices, COO is priced at $82.47, while KMTS trades at $26.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas KMTS's P/E ratio is -6.51. In terms of profitability, COO's ROE is +0.05%, compared to KMTS's ROE of -1.89%. Regarding short-term risk, COO is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check KMTS's competition here
COO vs QDEL Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, QDEL has a market cap of 1.5B. Regarding current trading prices, COO is priced at $82.47, while QDEL trades at $21.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas QDEL's P/E ratio is -1.35. In terms of profitability, COO's ROE is +0.05%, compared to QDEL's ROE of -0.46%. Regarding short-term risk, COO is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check QDEL's competition here
COO vs PLSE Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, PLSE has a market cap of 1.5B. Regarding current trading prices, COO is priced at $82.47, while PLSE trades at $20.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas PLSE's P/E ratio is -18.79. In terms of profitability, COO's ROE is +0.05%, compared to PLSE's ROE of -0.73%. Regarding short-term risk, COO is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check PLSE's competition here
COO vs AZTA Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, COO is priced at $82.47, while AZTA trades at $28.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas AZTA's P/E ratio is 50.48. In terms of profitability, COO's ROE is +0.05%, compared to AZTA's ROE of -0.03%. Regarding short-term risk, COO is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check AZTA's competition here
COO vs NVCR Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, NVCR has a market cap of 1.3B. Regarding current trading prices, COO is priced at $82.47, while NVCR trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas NVCR's P/E ratio is -7.06. In terms of profitability, COO's ROE is +0.05%, compared to NVCR's ROE of -0.50%. Regarding short-term risk, COO is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check NVCR's competition here
COO vs BLFS Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, BLFS has a market cap of 1.1B. Regarding current trading prices, COO is priced at $82.47, while BLFS trades at $22.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas BLFS's P/E ratio is -60.76. In terms of profitability, COO's ROE is +0.05%, compared to BLFS's ROE of -0.01%. Regarding short-term risk, COO is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check BLFS's competition here
COO vs NNNN Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, NNNN has a market cap of 1.1B. Regarding current trading prices, COO is priced at $82.47, while NNNN trades at $24.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas NNNN's P/E ratio is 411.67. In terms of profitability, COO's ROE is +0.05%, compared to NNNN's ROE of +0.11%. Regarding short-term risk, COO is more volatile compared to NNNN. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check NNNN's competition here
COO vs STAA Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, STAA has a market cap of 876.7M. Regarding current trading prices, COO is priced at $82.47, while STAA trades at $18.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas STAA's P/E ratio is -9.06. In terms of profitability, COO's ROE is +0.05%, compared to STAA's ROE of -0.27%. Regarding short-term risk, COO is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check STAA's competition here
COO vs ATRI Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, COO is priced at $82.47, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas ATRI's P/E ratio is 64.50. In terms of profitability, COO's ROE is +0.05%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, COO is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check ATRI's competition here
COO vs ANGO Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, ANGO has a market cap of 462.5M. Regarding current trading prices, COO is priced at $82.47, while ANGO trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas ANGO's P/E ratio is -16.75. In terms of profitability, COO's ROE is +0.05%, compared to ANGO's ROE of -0.15%. Regarding short-term risk, COO is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check ANGO's competition here
COO vs KRMD Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, KRMD has a market cap of 219.6M. Regarding current trading prices, COO is priced at $82.47, while KRMD trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas KRMD's P/E ratio is -59.25. In terms of profitability, COO's ROE is +0.05%, compared to KRMD's ROE of -0.22%. Regarding short-term risk, COO is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check KRMD's competition here
COO vs UTMD Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, UTMD has a market cap of 217.3M. Regarding current trading prices, COO is priced at $82.47, while UTMD trades at $67.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas UTMD's P/E ratio is 19.49. In terms of profitability, COO's ROE is +0.05%, compared to UTMD's ROE of +0.10%. Regarding short-term risk, COO is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check UTMD's competition here
COO vs OSUR Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, OSUR has a market cap of 201.1M. Regarding current trading prices, COO is priced at $82.47, while OSUR trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas OSUR's P/E ratio is -3.40. In terms of profitability, COO's ROE is +0.05%, compared to OSUR's ROE of -0.16%. Regarding short-term risk, COO is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check OSUR's competition here
COO vs STXS Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, STXS has a market cap of 192.7M. Regarding current trading prices, COO is priced at $82.47, while STXS trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas STXS's P/E ratio is -7.12. In terms of profitability, COO's ROE is +0.05%, compared to STXS's ROE of -2.49%. Regarding short-term risk, COO is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check STXS's competition here
COO vs SMTI Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, SMTI has a market cap of 182.7M. Regarding current trading prices, COO is priced at $82.47, while SMTI trades at $20.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas SMTI's P/E ratio is -28.40. In terms of profitability, COO's ROE is +0.05%, compared to SMTI's ROE of -1.28%. Regarding short-term risk, COO is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check SMTI's competition here
COO vs NYXH Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, NYXH has a market cap of 172.2M. Regarding current trading prices, COO is priced at $82.47, while NYXH trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas NYXH's P/E ratio is -1.73. In terms of profitability, COO's ROE is +0.05%, compared to NYXH's ROE of -1.01%. Regarding short-term risk, COO is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check NYXH's competition here
COO vs INFU Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, INFU has a market cap of 161.4M. Regarding current trading prices, COO is priced at $82.47, while INFU trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas INFU's P/E ratio is 30.52. In terms of profitability, COO's ROE is +0.05%, compared to INFU's ROE of +0.10%. Regarding short-term risk, COO is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check INFU's competition here
COO vs PDEX Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, PDEX has a market cap of 128.9M. Regarding current trading prices, COO is priced at $82.47, while PDEX trades at $40.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas PDEX's P/E ratio is 11.59. In terms of profitability, COO's ROE is +0.05%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, COO is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check PDEX's competition here
COO vs MBOT Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, MBOT has a market cap of 93.9M. Regarding current trading prices, COO is priced at $82.47, while MBOT trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas MBOT's P/E ratio is -4.58. In terms of profitability, COO's ROE is +0.05%, compared to MBOT's ROE of -0.37%. Regarding short-term risk, COO is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check MBOT's competition here
COO vs AKYA Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, COO is priced at $82.47, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas AKYA's P/E ratio is -1.34. In terms of profitability, COO's ROE is +0.05%, compared to AKYA's ROE of -6.72%. Regarding short-term risk, COO is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check AKYA's competition here
COO vs ZTEK Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, ZTEK has a market cap of 63.1M. Regarding current trading prices, COO is priced at $82.47, while ZTEK trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas ZTEK's P/E ratio is -8.40. In terms of profitability, COO's ROE is +0.05%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, COO is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check ZTEK's competition here
COO vs DXR Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, DXR has a market cap of 61.5M. Regarding current trading prices, COO is priced at $82.47, while DXR trades at $12.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas DXR's P/E ratio is 76.31. In terms of profitability, COO's ROE is +0.05%, compared to DXR's ROE of +0.05%. Regarding short-term risk, COO is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check DXR's competition here
COO vs STSS Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, STSS has a market cap of 52.2M. Regarding current trading prices, COO is priced at $82.47, while STSS trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas STSS's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to STSS's ROE of -0.91%. Regarding short-term risk, COO is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check STSS's competition here
COO vs OMIC Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, COO is priced at $82.47, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas OMIC's P/E ratio is -0.58. In terms of profitability, COO's ROE is +0.05%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, COO is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check OMIC's competition here
COO vs IGAP Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, COO is priced at $82.47, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas IGAP's P/E ratio is -10.52. In terms of profitability, COO's ROE is +0.05%, compared to IGAP's ROE of +1.21%. Regarding short-term risk, COO is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check IGAP's competition here
COO vs NEPH Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, NEPH has a market cap of 43.4M. Regarding current trading prices, COO is priced at $82.47, while NEPH trades at $3.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas NEPH's P/E ratio is 29.14. In terms of profitability, COO's ROE is +0.05%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, COO is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check NEPH's competition here
COO vs POCI Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, POCI has a market cap of 34.2M. Regarding current trading prices, COO is priced at $82.47, while POCI trades at $4.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas POCI's P/E ratio is -5.21. In terms of profitability, COO's ROE is +0.05%, compared to POCI's ROE of -0.61%. Regarding short-term risk, COO is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check POCI's competition here
COO vs EKSO Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, EKSO has a market cap of 29.3M. Regarding current trading prices, COO is priced at $82.47, while EKSO trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas EKSO's P/E ratio is -2.08. In terms of profitability, COO's ROE is +0.05%, compared to EKSO's ROE of -0.91%. Regarding short-term risk, COO is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check EKSO's competition here
COO vs SDC Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, COO is priced at $82.47, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas SDC's P/E ratio is -0.03. In terms of profitability, COO's ROE is +0.05%, compared to SDC's ROE of -1.96%. Regarding short-term risk, COO is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check SDC's competition here
COO vs HBIO Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, HBIO has a market cap of 26.1M. Regarding current trading prices, COO is priced at $82.47, while HBIO trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas HBIO's P/E ratio is -0.48. In terms of profitability, COO's ROE is +0.05%, compared to HBIO's ROE of -1.99%. Regarding short-term risk, COO is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check HBIO's competition here
COO vs IVC Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, COO is priced at $82.47, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas IVC's P/E ratio is -0.79. In terms of profitability, COO's ROE is +0.05%, compared to IVC's ROE of -0.46%. Regarding short-term risk, COO is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check IVC's competition here
COO vs ZJYL Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, ZJYL has a market cap of 22.9M. Regarding current trading prices, COO is priced at $82.47, while ZJYL trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas ZJYL's P/E ratio is 14.63. In terms of profitability, COO's ROE is +0.05%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, COO is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check ZJYL's competition here
COO vs MLSS Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, MLSS has a market cap of 20.3M. Regarding current trading prices, COO is priced at $82.47, while MLSS trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas MLSS's P/E ratio is -2.86. In terms of profitability, COO's ROE is +0.05%, compared to MLSS's ROE of -1.65%. Regarding short-term risk, COO is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check MLSS's competition here
COO vs RVP Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, RVP has a market cap of 20.1M. Regarding current trading prices, COO is priced at $82.47, while RVP trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas RVP's P/E ratio is -3.05. In terms of profitability, COO's ROE is +0.05%, compared to RVP's ROE of -0.08%. Regarding short-term risk, COO is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check RVP's competition here
COO vs RGNT Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, RGNT has a market cap of 16.1M. Regarding current trading prices, COO is priced at $82.47, while RGNT trades at $3.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas RGNT's P/E ratio is -3.71. In terms of profitability, COO's ROE is +0.05%, compared to RGNT's ROE of N/A. Regarding short-term risk, COO is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check RGNT's competition here
COO vs FEMY Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, FEMY has a market cap of 15.9M. Regarding current trading prices, COO is priced at $82.47, while FEMY trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas FEMY's P/E ratio is -0.78. In terms of profitability, COO's ROE is +0.05%, compared to FEMY's ROE of -7.64%. Regarding short-term risk, COO is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check FEMY's competition here
COO vs NXGL Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, NXGL has a market cap of 12.9M. Regarding current trading prices, COO is priced at $82.47, while NXGL trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas NXGL's P/E ratio is -3.36. In terms of profitability, COO's ROE is +0.05%, compared to NXGL's ROE of -0.55%. Regarding short-term risk, COO is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check NXGL's competition here
COO vs NXGLW Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, NXGLW has a market cap of 8.6M. Regarding current trading prices, COO is priced at $82.47, while NXGLW trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas NXGLW's P/E ratio is -0.08. In terms of profitability, COO's ROE is +0.05%, compared to NXGLW's ROE of -0.55%. Regarding short-term risk, COO is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check NXGLW's competition here
COO vs LUCY Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, LUCY has a market cap of 5.1M. Regarding current trading prices, COO is priced at $82.47, while LUCY trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas LUCY's P/E ratio is -0.55. In terms of profitability, COO's ROE is +0.05%, compared to LUCY's ROE of -0.00%. Regarding short-term risk, COO is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check LUCY's competition here
COO vs NSTG Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, COO is priced at $82.47, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas NSTG's P/E ratio is -0.03. In terms of profitability, COO's ROE is +0.05%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, COO is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check NSTG's competition here
COO vs MHUA Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, MHUA has a market cap of 3.2M. Regarding current trading prices, COO is priced at $82.47, while MHUA trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas MHUA's P/E ratio is 0.32. In terms of profitability, COO's ROE is +0.05%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, COO is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check MHUA's competition here
COO vs GMVD Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, COO is priced at $82.47, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas GMVD's P/E ratio is -0.01. In terms of profitability, COO's ROE is +0.05%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, COO is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check GMVD's competition here
COO vs GMVDW Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, COO is priced at $82.47, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas GMVDW's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, COO is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check GMVDW's competition here
COO vs POAI Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, POAI has a market cap of 1.7M. Regarding current trading prices, COO is priced at $82.47, while POAI trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas POAI's P/E ratio is -0.02. In terms of profitability, COO's ROE is +0.05%, compared to POAI's ROE of +4.25%. Regarding short-term risk, COO is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check POAI's competition here
COO vs AVGR Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, COO is priced at $82.47, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas AVGR's P/E ratio is -0.05. In terms of profitability, COO's ROE is +0.05%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, COO is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check AVGR's competition here
COO vs GCTK Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, GCTK has a market cap of 868.2K. Regarding current trading prices, COO is priced at $82.47, while GCTK trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas GCTK's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to GCTK's ROE of -26.59%. Regarding short-term risk, COO is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check GCTK's competition here
COO vs LUCYW Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, LUCYW has a market cap of 320.5K. Regarding current trading prices, COO is priced at $82.47, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas LUCYW's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to LUCYW's ROE of -0.00%. Regarding short-term risk, COO is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check LUCYW's competition here
COO vs WOK Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, WOK has a market cap of 8.1K. Regarding current trading prices, COO is priced at $82.47, while WOK trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas WOK's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to WOK's ROE of -0.07%. Regarding short-term risk, COO is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for COO.Check WOK's competition here
COO vs IIN Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, IIN has a market cap of 0. Regarding current trading prices, COO is priced at $82.47, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas IIN's P/E ratio is 226.45. In terms of profitability, COO's ROE is +0.05%, compared to IIN's ROE of -0.00%. Regarding short-term risk, COO is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check IIN's competition here
COO vs HRC Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, HRC has a market cap of 0. Regarding current trading prices, COO is priced at $82.47, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas HRC's P/E ratio is 41.92. In terms of profitability, COO's ROE is +0.05%, compared to HRC's ROE of +0.14%. Regarding short-term risk, COO is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check HRC's competition here
COO vs ARTC Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, ARTC has a market cap of 0. Regarding current trading prices, COO is priced at $82.47, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas ARTC's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to ARTC's ROE of N/A. Regarding short-term risk, COO is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check ARTC's competition here
COO vs APR Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, APR has a market cap of 0. Regarding current trading prices, COO is priced at $82.47, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas APR's P/E ratio is 22.59. In terms of profitability, COO's ROE is +0.05%, compared to APR's ROE of +9.81%. Regarding short-term risk, COO is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check APR's competition here
COO vs ATRS Comparison February 2026
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.7B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, COO is priced at $82.47, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 44.96, whereas ATRS's P/E ratio is 14.95. In terms of profitability, COO's ROE is +0.05%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, COO is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for COO.Check ATRS's competition here